5,7,4′-Trimethoxyflavone triggers cancer cell PD-L1 ubiquitin–proteasome degradation and facilitates antitumor immunity by targeting HRD1

Abstract

Targeting the programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) pathway has been identified as a successful approach for tumor immunotherapy. Here, we identified that the small molecule 5,7,4′-trimethoxyflavone (TF) from Kaempferia parviflora Wall reduces PD-L1 expression in colorectal cancer cells and enhances the killing of tumor cells by T cells. Mechanistically, TF targets and stabilizes the ubiquitin ligase HMG-CoA reductase degradation protein 1 (HRD1), thereby increasing the ubiquitination of PD-L1 and promoting its degradation through the proteasome pathway. In mouse MC38 xenograft tumors, TF can activate tumor-infiltrating T-cell immunity and reduce the immunosuppressive infiltration of myeloid-derived suppressor cells and regulatory T cells, thus exerting antitumor effects. Moreover, TF synergistically exerts antitumor immunity with CTLA-4 antibody. This study provides new insights into the antitumor mechanism of TF and suggests that it may be a promising small molecule immune checkpoint modulator for cancer therapy.

Keywords

5,7,4′-trimethoxyflavone / colorectal cancer / HRD1 / PD-L1

References

1	RL Siegel, KD Miller, HE Fuchs, A Jemal. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7-33. doi:
2	GJ van der Bij, SJ Oosterling, RH Beelen, S Meijer, JC Coffey, M van Egmond. The perioperative period is an underutilized window of therapeutic opportunity in patients with colorectal cancer. Ann Surg. 2009;249(5):727-734. doi:
3	T André, C Boni, M Navarro, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109-3116. doi:
4	RM Samstein, CH Lee, AN Shoushtari, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202-206. doi:
5	D Bedognetti, M Ceccarelli, L Galluzzi, et al. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. J Immunother Cancer. 2019;7(1):131. doi:
6	JH Cha, LC Chan, CW Li, JL Hsu, MC Hung. Mechanisms controlling PD-L1 expression in cancer. Mol Cell. 2019;76(3):359-370. doi:
7	X Chen, X Pan, W Zhang, et al. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses. Acta Pharm Sin B. 2020;10(5):723-733. doi:
8	SL Topalian, CG Drake, DM Pardoll. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24(2):207-212. doi:
9	A Ribas, JD Wolchok. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350-1355. doi:
10	Y Iwai, J Hamanishi, K Chamoto, T Honjo. Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci. 2017;24(1):26. doi:
11	T Maj, W Wang, J Crespo, et al. Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat Immunol. 2017;18(12):1332-1341. doi:
12	M Yarchoan, A Hopkins, EM Jaffee. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500-2501. doi:
13	Q Gou, C Dong, H Xu, et al. PD-L1 degradation pathway and immunotherapy for cancer. Cell Death Dis. 2020;11(11):955. doi:
14	H Yamaguchi, JM Hsu, WH Yang, MC Hung. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. Nat Rev Clin Oncol. 2022;19(5):287-305. doi:
15	A Ciechanover, H Heller, S Elias, AL Haas, A Hershko. ATP-dependent conjugation of reticulocyte proteins with the polypeptide required for protein degradation. Proc Natl Acad Sci USA. 1980;77(3):1365-1368. doi:
16	JH Cha, WH Yang, W Xia, et al. Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1. Mol Cell. 2018;71(4):606-620. doi:
17	J Zhang, X Bu, H Wang, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature. 2018;553(7686):91-95. doi:
18	Z Tang, PG Pilié, C Geng, et al. ATR inhibition induces CDK1-SPOP signaling and enhances anti-PD-L1 cytotoxicity in prostate cancer. Clin Cancer Res. 2021;27(17):4898-4909. doi:
19	J Zou, H Xia, C Zhang, et al. Casp8 acts through A20 to inhibit PD-L1 expression: the mechanism and its implication in immunotherapy. Cancer Sci. 2021;112(7):2664-2678. doi:
20	Y Wu, C Zhang, X Liu, et al. ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation. Nat Commun. 2021;12(1):2346. doi:
21	ML Burr, CE Sparbier, YC Chan, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Research Support, Non-U S Gov't. Nature. 2017;549(7670):101-105.
22	G Qian, J Guo, KA Vallega, et al. Membrane-associated RING-CH 8 functions as a novel PD-L1 E3 ligase to mediate PD-L1 degradation induced by EGFR inhibitors. Mol Cancer Res. 2021;19(10):1622-1634. doi:
23	X Liu, M Yin, J Dong, et al. Tubeimoside-1 induces TFEB-dependent lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting mTOR. Acta Pharm Sin B. 2021;11(10):3134-3149. doi:
24	Y Wang, Q Sun, N Mu, et al. The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells. Cell Commun Signal. 2020;18(1):112. doi:
25	D Zhu, R Xu, X Huang, et al. Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1. Cell Death Differ. 2021;28(6):1773-1789. doi:
26	SO Lim, CW Li, W Xia, et al. Deubiquitination and stabilization of PD-L1 by CSN5. Cancer Cell. 2016;30(6):925-939. doi:
27	S Doroudgar, M V?lkers, DJ Thuerauf, et al. Hrd1 and ER-associated protein degradation, ERAD, are critical elements of the adaptive ER stress response in cardiac myocytes. Circ Res. 2015;117(6):536-546. doi:
28	Y Xu, D Fang. Endoplasmic reticulum-associated degradation and beyond: the multitasking roles for HRD1 in immune regulation and autoimmunity. J Autoimmun. 2020;109:102423. doi:
29	K Li, K Zhang, H Wang, et al. Hrd1-mediated ACLY ubiquitination alleviate NAFLD in db/db mice. Metabolism. 2021;114:154349. doi:
30	CJ Proctor, DA Gray. GSK3 and p53 - is there a link in Alzheimer's disease? Mol Neurodegener. 2010;5:7. doi:
31	S Yamasaki, N Yagishita, T Sasaki, et al. Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase ‘Synoviolin’. Embo J. 2007;26(1):113-122. doi:
32	S Yamasaki, N Yagishita, K Nishioka, T Nakajima. The roles of synoviolin in crosstalk between endoplasmic reticulum stress-induced apoptosis and p53 pathway. Cell Cycle. 2007;6(11):1319-1323. doi:
33	W Xie, L Shi, H Quan, et al. SYVN1 ubiquitinates FoxO1 to induce β-catenin nuclear translocation, PD-L1-mediated metastasis, and immune evasion of hepatocellular carcinoma. Cell Oncol (Dordr). 2023;46(5):1285-1299. doi:
34	C Rujjanawate, D Kanjanapothi, D Amornlerdpison, S Pojanagaroon. Anti-gastric ulcer effect of Kaempferia parviflora. J Ethnopharmacol. 2005;102(1):120-122. doi:
35	C Sae-Wong, H Matsuda, S Tewtrakul, et al. Suppressive effects of methoxyflavonoids isolated from Kaempferia parviflora on inducible nitric oxide synthase (iNOS) expression in RAW 264.7 cells. J Ethnopharmacol. 2011;136(3):488-495. doi:
36	C Sae-wong, P Tansakul, S Tewtrakul. Anti-inflammatory mechanism of Kaempferia parviflora in murine macrophage cells (RAW 264.7) and in experimental animals. J Ethnopharmacol. 2009;124(3):576-580. doi:
37	Y Okabe, T Shimada, T Horikawa, et al. Suppression of adipocyte hypertrophy by polymethoxyflavonoids isolated from Kaempferia parviflora. Phytomedicine. 2014;21(6):800-806. doi:
38	L Chen. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol. 2004;4(5):336-347. doi:
39	Y Wang, H Wang, H Yao, C Li, JY Fang, J Xu. Regulation of PD-L1: emerging routes for targeting tumor immune evasion. Front Pharmacol. 2018;9:536. doi:
40	MK Callahan, MA Postow, JD Wolchok. CTLA-4 and PD-1 pathway blockade: combinations in the clinic. Front Oncol. 2014;4:385. doi:
41	Y Liu, X Liu, N Zhang, et al. Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5. Acta Pharm Sin B. 2020;10(12):2299-2312. doi:
42	Q Wang, J Wang, D Yu, et al. Benzosceptrin C induces lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting DHHC3. Cell Rep Med. 2024;5(2):101357. doi:
43	MG Elhennawy, HS Lin. Quantification of apigenin trimethyl ether in rat plasma by liquid chromatography-tandem mass spectrometry: application to a pre-clinical pharmacokinetic study. J Pharm Biomed Anal. 2017;142:35-41. doi:
44	MG Elhennawy, HS Lin. Dose- and time-dependent pharmacokinetics of apigenin trimethyl ether. Eur J Pharm Sci. 2018;118:96-102. doi: